Drug details

Evenity (romosozumab-aqqg injection)

type of Monoclonal Antibodies, Diagnostics, Endocrine, Monoclonal Antibodies, Endocrine

Evenity (romosozumab-aqqg) is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

The drug is often used to treat Osteoporosis .

This drug may have the following side effects:

• headache,
• joint pain,
• weakness,
• insomnia,
• swelling of extremities,
• muscle spasms,
• neck pain,
• numbness and
• tingling sensation

The following drugs are related to Evenity, either as a replacement or used together:

• Actonel (risedronate sodium)
• Humira (adalimumab injection solution for subcutaneous administration)
• Fosamax (alendronate sodium)
• Fosamax Plus D (alendronate sodium and cholecalciferol)
• Imuran (azathioprine)
• Boniva (ibandronate sodium)
• Boniva Injection (ibandronate sodium injection)
• Cosentyx (secukinumab injection)
• Xgeva (denosumab)
• Prolia (denosumab injection)
• Forteo (teriparatide (rdna origin) injection)
• Remicade (infliximab)
• Prednisone (prednisone tablets, usp)
• Reclast (zoledronic acid injection)
• Zometa (zoledronic acid for inj)